MSMaryam Shojaei

Maryam Shojaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryam Shojaei has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular landscape of respiratory infection: A large-scale, multi-centre blood transcriptome dataset

    by Tracy Chew, Tiana M. Pelaia, Amy L. Phu, Sally Teoh, Ya Wang, Nandan Deshpande, Karan Kim, Velma Herwanto, Gunawan, Thomas Karvunidis, et al.

    Respiratory infections pose significant challenges to global health, impacting millions of individuals annually. Understanding the molecular mechanisms underlying the pathogenicity of these infections is crucial for developing effective interventions. RNA sequencing provides insights into a patient’s global transcriptome changes, facilitating the identification of host gene signatures in response to infection and potential therapeutic targets. Here we present an extensive whole blood transcriptome dataset from a demographically diverse cohort of 502 patients with infections including COVID-19, seasonal coronavirus, influenza A or influenza B, sepsis, septic shock, and co-infections (Viral/Viral, Bacterial/Viral, Bacterial/Viral/Fungal, Viral/Fungal, Viral/ Viral/Fungal). The cohort size and depth of data showcase its potential to unravel respiratory infection pathogenesis for the development of better diagnostics, treatments, and preventive strategies for respiratory infections and future global health crises.


  • Open Access

    Evaluating the InSignia IFI27 expression assay for detecting viral respiratory infection compared to a traditional gene normalisation assay

    by Tiana M. Pelaia, Karan Kim, Nicole Lima, Claire Gibbs, Lee M. Smith, Sally Teoh, Ya Wang, Colin Denver, Elisa Mokany, Alison Todd, et al.

    Host gene expression is crucial for understanding disease progression and developing diagnostic biomarkers. Previously, we identified a novel immune biomarker IFI27, validated with routine RT-qPCR methods employed in a research setting, that discriminates between influenza and bacteria in patients with suspected respiratory infection. This study aimed to assess the In Signia method, which employs a novel gene normalization technique to yield a variable transcript analysis (VITA) index. The VITA index measures gene expression relative to a non-transcribed region of DNA, such that it is independent of sample quality or quantity. We compared IFI27 gene expression measured by the In Signia assay to that of the research assay in blood samples collected from patients with respiratory diseases and SARS-CoV-2 vaccinated individuals. The study found a strong correlation and acceptable agreement between traditional ΔCq methods and In Signia for IFI27 levels in the higher range (log(ΔCq)Research > 1), but not for IFI27 expression levels below this range, likely due to the different normalization strategies. Notably the In Signia assay was more sensitive in detecting viral infection among hospital patients. These findings suggest that the In Signia assay, which supports high throughput workflows, may be used for the rapid detection of viral infection in patients with respiratory symptoms.

  • Open Access

    Host transcriptomics and machine learning for secondary bacterial infections in patients with COVID-19: a prospective, observational cohort study

    by Meagan Carney, Tiana Maria Pelaia, Tracy Chew, Sally Teoh, Amy Phu, Karan Kim, Ya Wang, Jonathan Iredell, Yoann Zerbib, Anthony McLean, et al.


  • Open Access

    Multisite validation of a host response signature for predicting likelihood of bacterial and viral infections in patients with suspected influenza

    by Maryam Shojaei, Uan‐I Chen, Uros Midic, Simone Thair, Sally Teoh, Anthony McLean, Timothy E. Sweeney, Matthew Thompson, Oliver Liesenfeld, Purvesh Khatri, et al.

    Background: Indiscriminate use of antimicrobials and antimicrobial resistance is a public health threat. IMX‐BVN‐1, a 29‐host mRNA classifier, provides two separate scores that predict likelihoods of bacterial and viral infections in patients with suspected acute infections. We validated the performance of IMX‐BVN‐1 in adults attending acute health care settings with suspected influenza.Method: We amplified 29‐host response genes in RNA extracted from blood by NanoString nCounter. IMX‐BVN‐1 calculated two scores to predict probabilities of bacterial and viral infections. Results were compared against the infection status (no infection; highly probable/possible infection; confirmed infection) determined by clinical adjudication.Results: Amongst 602 adult patients (74.9% ED, 16.9% ICU, 8.1% outpatients), 7.6% showed in‐hospital mortality and 15.5% immunosuppression. Median IMX‐BVN‐1 bacterial and viral scores were higher in patients with confirmed bacterial (0.27) and viral (0.62) infections than in those without bacterial (0.08) or viral (0.21) infection, respectively. The AUROC distinguishing bacterial from nonbacterial illness was 0.81 and 0.87 when distinguishing viral from nonviral illness. The bacterial top quartile's positive likelihood ratio (LR) was 4.38 with a rule‐in specificity of 88%; the bacterial bottom quartile's negative LR was 0.13 with a rule‐out sensitivity of 96%. Similarly, the viral top quartile showed an infinite LR with rule‐in specificity of 100%; the viral bottom quartile had a LR of 0.22 and a rule‐out sensitivity of 85%.Conclusion: IMX‐BVN‐1 showed high accuracy for differentiating bacterial and viral infections from noninfectious illness in patients with suspected influenza. Clinical utility of IMX‐BVN will be validated following integration into a point of care system.


  • Open Access

    Pathway and Network Analyses Identify Growth Factor Signaling and MMP9 as Potential Mediators of Mitochondrial Dysfunction in Severe COVID-19

    by Ya Wang, Klaus Schughart, Tiana Maria Pelaia, Tracy Chew, Karan Kim, Thomas Karvunidis, Ben Knippenberg, Sally Teoh, Amy L. Phu, Kirsty R. Short, et al.

    Patients with preexisting metabolic disorders such as diabetes are at a higher risk of developing severe coronavirus disease 2019 (COVID-19). Mitochondrion, the very organelle that controls cellular metabolism, holds the key to understanding disease progression at the cellular level. Our current study aimed to understand how cellular metabolism contributes to COVID-19 outcomes. Metacore pathway enrichment analyses on differentially expressed genes (encoded by both mitochondrial and nuclear deoxyribonucleic acid (DNA)) involved in cellular metabolism, regulation of mitochondrial respiration and organization, and apoptosis, was performed on RNA sequencing (RNASeq) data from blood samples collected from healthy controls and patients with mild/moderate or severe COVID-19. Genes from the enriched pathways were analyzed by network analysis to uncover interactions among them and up- or downstream genes within each pathway. Compared to the mild/moderate COVID-19, the upregulation of a myriad of growth factor and cell cycle signaling pathways, with concomitant downregulation of interferon signaling pathways, were observed in the severe group. Matrix metallopeptidase 9 (MMP9) was found in five of the top 10 upregulated pathways, indicating its potential as therapeutic target against COVID-19. In summary, our data demonstrates aberrant activation of endocrine signaling in severe COVID-19, and its implication in immune and metabolic dysfunction.


  • Open Access

    IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

    by Maryam Shojaei, Amir Shamshirian, James Monkman, Laura Grice, Minh Tran, Chin Wee Tan, Siok Min Teo, Gustavo Rodrigues Rossi, Timothy R. McCulloch, Marek Nalos, et al.

    Purpose: Robust biomarkers that predict disease outcomes amongst COVID-19 patients are necessary for both patient triage and resource prioritisation. Numerous candidate biomarkers have been proposed for COVID-19. However, at present, there is no consensus on the best diagnostic approach to predict outcomes in infected patients. Moreover, it is not clear whether such tools would apply to other potentially pandemic pathogens and therefore of use as stockpile for future pandemic preparedness.Methods: We conducted a multi-cohort observational study to investigate the biology and the prognostic role of interferon alpha-inducible protein 27 (IFI27) in COVID-19 patients.Results: We show that IFI27 is expressed in the respiratory tract of COVID-19 patients and elevated IFI27 expression in the lower respiratory tract is associated with the presence of a high viral load. We further demonstrate that the systemic host response, as measured by blood IFI27 expression, is associated with COVID-19 infection. For clinical outcome prediction (e.g., respiratory failure), IFI27 expression displays a high sensitivity (0.95) and specificity (0.83), outperforming other known predictors of COVID-19 outcomes. Furthermore, IFI27 is upregulated in the blood of infected patients in response to other respiratory viruses. For example, in the pandemic H1N1/09 influenza virus infection, IFI27-like genes were highly upregulated in the blood samples of severely infected patients.Conclusion: These data suggest that prognostic biomarkers targeting the family of IFI27 genes could potentially supplement conventional diagnostic tools in future virus pandemics, independent of whether such pandemics are caused by a coronavirus, an influenza virus or another as yet-to-be discovered respiratory virus.


  • Open Access

    Neutrophil-to-Lymphocyte Ratio Cut-Off Point for COVID-19 Mortality: A Retrospective Study

    by Zahedin Kheyri, Sepehr Metanat, Hadiseh Hosamirudsari, Samaneh Akbarpour, Maryam Shojaei, Neda Faraji, Fariba Mansouri, Fatemeh Taghizadeh, Fatemeh Ahmadian

    Several months have passed since the onset of the COVID-19 pandemic. Multiple characteristics have been proposed as prognostic factors so far. This study aims to provide evidence on the association of neutrophil-to-lymphocyte ratio (NLR) at the hospitalization time and three desired outcomes (mortality, prolonged hospitalization, and intensive care unit [ICU] admission). We designed a single-centre retrospective observational study in Baharloo Hospital (Tehran, Iran) from 20 February to 19 April 2020. Patients with confirmed COVID-19 diagnosis via rt-PCR or chest CT imaging were included. Demographic and clinical data were obtained. The sample was divided into three groups, using tertile boundaries of initial NLR. The differences in mortality, comorbidities, hospitalization duration, drug administration, and ICU admission between these three groups were investigated. The identified confounding factors were adjusted to calculate the odds ratio of death, ICU admission, and prolonged hospitalization. Nine hundred sixty-three patients were included. In total, 151 and 212 participants experienced mortality and ICU admission, respectively. In multivariate logistic regression models, the adjusted odds ratio for mortality event in the second and third tertile of initial NLR after full adjustment were 1.89 (95% CI:1.07-3.32) and 2.57 (95% CI:1.48-4.43) and for ICU admission were 1.85 (95% CI:1.14-3.01) and 2.88 (95% CI:1.79-4.61), respectively. The optimal cut-off value of the initial NLR for predicting mortality was 4.27. Initial NLR can predict mortality and ICU admission in COVID-19 patients. Further investigations for curating the calculated cut-off can propose initial NLR as an indicator of poor prognosis for COVID-19 patients.


  • Open Access

    IFI27 transcription is an early predictor for COVID-19 outcomes; a multi-cohort observational study

    by Maryam Shojaei, Amir Shamshirian, James Monkman, Laura Grice, Minh Tran, Chin Wee Tan, Gustavo Rodrigues Rossi, Timothy R. McCulloch, Marek Nalos, Keng Yih Chew, et al.

    Background: Robust biomarkers that predict disease outcomes amongst COVID-19 patients are necessary for both patient triage and resource prioritisation. Numerous candidate biomarkers have been proposed for COVID-19. However, at present, there is no consensus on the best diagnostic approach to predict outcomes in infected patients. Moreover, it is not clear whether such tools would apply to other potentially pandemic pathogens and therefore of use as stockpile for future pandemic preparedness. Methods: We conducted a multi-cohort observational study to investigate the biology and the prognostic role of interferon alpha-inducible protein 27 ( IFI27 ) in COVID-19 patients. Findings: We show that IFI27 is expressed in the respiratory tract of COVID-19 patients and elevated IFI27 expression is associated with the presence of a high viral load. We further demonstrate that systemic host response, as measured by blood IFI27 expression, is associated with COVID-19 severity. For clinical outcome prediction (e.g. respiratory failure), IFI27 expression displays a high positive (0.83) and negative (0.95) predictive value, outperforming all other known predictors of COVID-19 severity. Furthermore, IFI27 is upregulated in the blood of infected patients in response to other respiratory viruses. For example, in the pandemic H1N1/09 swine influenza virus infection, IFI27- like genes were highly upregulated in the blood samples of severely infected patients. Interpretation: These data suggest that prognostic biomarkers targeting the family of IFI27 genes could potentially supplement conventional diagnostic tools in future virus pandemics, independent of whether such pandemics are caused by a coronavirus, an influenza virus or another as yet-to-be discovered respiratory virus. Research in context: Evidence before this study: We searched the scientific literature using PubMed to identify studies that used the IFI27 biomarker to predict outcomes in COVID-19 patients. We used the search terms “ IFI27 ”, “COVID-19, “gene expression” and “outcome prediction”. We did not identify any study that investigated the role of IFI27 biomarker in outcome prediction. Although ten studies were identified using the general terms of “gene expression” and “COVID-19”, IFI27 was only mentioned in passing as one of the identified genes. All these studies addressed the broader question of the host response to COVID-19; none focused solely on using IFI27 to improve the risk stratification of infected patients in a pandemic. Added value of this study: Here, we present the findings of a multi-cohort study of the IFI27 biomarker in COVID-19 patients. Our findings show that the host response, as reflected by blood IFI27 gene expression, accurately predicts COVID-19 disease progression (positive and negative predictive values; 0.83 and 0.95, respectively), outperforming age, comorbidity, C-reactive protein and all other known risk factors. The strong association of IFI27 with disease severity occurs not only in SARS-CoV-2 infection, but also in other respiratory viruses with pandemic potential, such as the influenza virus. These findings suggest that host response biomarkers, such as IFI27 , could help identify high-risk COVID-19 patients - those who are more likely to develop infection complications - and therefore may help improve patient triage in a pandemic. Implications of all the available evidence: This is the first systemic study of the clinical role of IFI27 in the current COVID-19 pandemic and its possible future application in other respiratory virus pandemics. The findings not only could help improve the current management of COVID-19 patients but may also improve future pandemic preparedness.


  • Open Access

    Reasons for delayed spinal cord decompression in individuals with traumatic spinal cord injuries in Iran: A qualitative study from the perspective of neurosurgeons

    by Masoud SohrabiAsl, Zahra Ghodsi, Roya Habibi Arejan, Zahra Azadmanjir, Mahdi Sharif-Alhoseini, Moein Khormali, Maryam Shojaei, Abbas Rahimiforoushani, Alireza Khoshnevisan, Alexander R. Vaccaro, et al.